Sign up to save your podcasts
Or
Share Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.
View all episodes
By Rahul Banerjee, MD
4.8
2626 ratings
Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.
More shows like The HemOnc Pulse
View all
JAMA Editors' Summary
139 Listeners
Research To Practice | Oncology Videos
111 Listeners
Making Sense with Sam Harris
26,353 Listeners
The Hematologist
27 Listeners
OncoPharm
182 Listeners
VJHemOnc Podcast
2 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
360 Listeners
Blood Podcast
56 Listeners
The Curious Clinicians
367 Listeners
Healthcare Unfiltered
136 Listeners
ASTCT Talks
8 Listeners
WolverHeme Happy Hour
29 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
40 Listeners